Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes…

Overview of attention for article published in Cardiovascular Diabetology, September 2013

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 public wall posts from 2 users.

Fomos os primeiros....estamos com os segundos e certamente com a equipa que somos estaremos em todos os possiveis...

Mais um degrau... o nosso trabalho no estudo http://www.cardiab.com/content/12/1/129

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.